Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Clinical Results For New Treatment Of Bacterial Vaginosis Infection

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for...

88 Percent Of UK Doctors Believe Whiplash Claims Are Exaggerated

AXA, a UK car insurer, has surveyed UK doctors as part of its ongoing campaign to understand the...

On Facebook, Women Are More Plentiful But Men Are Better Ad Targets

Global digital marketing companies Resolution Media and Kenshoo Social published a new report today...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

Blogroll

BERLIN, October 21 /PRNewswire/ --

- Global Report Launch: Energy [R]evolution: Global Sustainable Energy Outlook

Dear Sir or Madam,

DETROIT, October 21 /PRNewswire/ --

LONDON, October 20 /PRNewswire/ --

United Business Media (UBM) announces that Adrian Barrick is appointed to the position of CEO of its Built Environment division.

CAMBRIDGE, Massachusetts, October 20 /PRNewswire/ --

- Abt Associates to Lead Group of Firms to Strengthen Governance and Sustainable Health Reform

MCKINNEY, Texas, October 20 /PRNewswire/ --

Torchmark Corporation (NYSE: TMK) will release Third Quarter 2008 earnings after the market closes on Wednesday, October 22, 2008. In conjunction with Torchmark's Third Quarter 2008 Earnings Release, you are invited to listen to a conference call that will be broadcast live over the Internet on Thursday, October 23, 2008 at 11:00 a.m. Eastern. At that time a copy of the Company's Q3-2008 earnings press release and any other financial and statistical information about the quarter will be available on the Company's website at www.torchmarkcorp.com on the Investor Relations page.

PRINCETON, New Jersey, October 21 /PRNewswire/ --

-Laureate to Manufacture Tolerx's TRX518 Antibody

Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it has entered into a cGMP contract manufacturing agreement with Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for the treatment of immune-mediated diseases. Under the agreement, Laureate will produce Tolerx's humanized anti-GITR antibody known as TRX518, which is currently in development for cancer and chronic viral indications. Details of the agreement were not disclosed.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO)